Inocras Raises $31 Million to Accelerate U.S. Expansion of Whole-Genome Sequencing Platform for Precision Oncology Inocras Inc., a bioinformatics-driven precision medicine company specializing in whole-genome sequencing (WGS) and advanced genomic…
Spruce Biosciences Appoints Dr. Jessica Cohen Pfeffer as Vice President of Clinical Development to Advance Rare Neurological Disease Pipeline Spruce Biosciences, Inc., a late-stage biopharmaceutical company dedicated to developing and…
Family Heart Foundation Founder Katherine Wilemon Receives ASPC 2026 Honorary Fellow Award for Advancing Cardiovascular Disease Prevention The Family Heart Foundation, a leading nonprofit organization dedicated to research, education, advocacy,…
Pilatus Biosciences to Present Preclinical Data Highlighting PLT012’s Disease-Modifying Potential in COPD at ERS International Congress 2026 Pilatus Biosciences, a clinical-stage biopharmaceutical company focused on developing innovative metabolic checkpoint immunotherapies…
Seaport Therapeutics Reports Second Quarter 2026 Results, Highlights Positive Clinical Progress and Strengthened Financial Position Following IPO Seaport Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for…
Korsana Biosciences Strengthens Executive Leadership as KRSA-028 Advances Toward Clinical Development for Alzheimer’s Disease Korsana Biosciences, Inc., a biotechnology company focused on discovering and developing innovative therapies for neurodegenerative disorders,…
Zai Lab’s DLL3-Targeting ADC Receives FDA Orphan Drug Designation for Neuroendocrine Carcinomas Zai Lab Limited has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Rocket Pharmaceuticals Reports Positive Early Safety Update for RP-A501 Phase 2 Trial in Danon Disease Rocket Pharmaceuticals, Inc. has announced encouraging early safety results from the first three patients treated…
Polpharma Biologics Advances PB016 as FDA and EMA Accept Biosimilar Applications for Review Polpharma Biologics International AG has announced a significant regulatory milestone with the acceptance of both its Biologics…
Bayer Submits New Drug Application in China to Expand Finerenone Use for Adults with Non-Diabetic Chronic Kidney Disease Bayer has announced the submission of a New Drug Application (NDA) to…
Novo Nordisk Reports Topline Results from Phase 3 ZEUS Trial Evaluating Ziltivekimab for Cardiovascular Risk Reduction Novo Nordisk has announced topline findings from its pivotal Phase 3 ZEUS cardiovascular outcomes…
EU Approval Positions Datroway® as the Only TROP2-Targeted Therapy with Overall Survival Benefit in First-Line Metastatic TNBC The European Commission (EC) has approved Datroway® (datopotamab deruxtecan) as a monotherapy for…